• Eurobio Scientific closed the acquisition of CareDx’s Lab Products division, including CareDx AB in Sweden and subsidiaries in the US and Australia.
• Cash purchase price set at EUR 145 million, subject to customary adjustments.
• Deal expands GenDx’s transplantation IVD workflow coverage, spanning pre-transplant HLA typing to post-transplant monitoring.
• Combination adds scale in the US, Europe, and Asia-Pacific, leveraging complementary HLA typing kits, NGS assays, and software.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurobio Scientific SA published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.